Trials / Withdrawn
WithdrawnNCT04770831
Patients Who Receive 131 I-MIBG
An Observational Study of Patients With Recurrent Progressive or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Who Receive 131 I- MIBG
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 1 Year – 30 Years
- Healthy volunteers
- Not accepted
Summary
This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. The purpose of this study is to evaluate quality of life and response rate to 131 I-MIBG treatment.
Detailed description
This is an observational, single institution study designed to determine the benefit of 131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumors. Response rate, time to progression, and quality of life changes will be evaluated.
Conditions
Timeline
- Start date
- 2021-03-10
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2021-02-25
- Last updated
- 2022-12-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04770831. Inclusion in this directory is not an endorsement.